Novel drug therapy targets aggressive form of non-Hodgkin's lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL ...
Dec 10, 2012
0
0